Ardelyx’s (ARDX) strides in the internal medicine sector have put it on a promising growth trajectory. The company has experienced solid growth and demonstrated financial results that beat recent expectations, driven by impressive Q2 2024 net product sales revenues. In addition, the company projects an optimistic outlook for the rest of 2024. With various developments in the pipeline, Ardelyx offers an intriguing investment opportunity in the biopharmaceutical industry.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Ardelyx’s Pipeline Producing Results
Ardelyx is a biopharmaceutical company focusing on gastrointestinal and cardiorenal treatments. Its product portfolio includes Tenapanor, which treats irritable bowel syndrome with constipation (IBS-C), and XPHOZAH, which reduces serum phosphorus in adults with chronic kidney disease (CKD) on dialysis.
Recently, the company has seen positive signs of adoption of IBSRELA, recording $35.4 million in net product sales revenue in Q2 2024, marking a 25% growth quarter-over-quarter from Q1 2024. Similarly, XPHOZAH recorded $37.1 million in net product sales revenue during Q2 2024, showing significant growth compared to $15.2 million in the first quarter. However, recent CMS policies might hinder access to XPHOZAH, leading Ardelyx to take legal action to assure patient access to the drug.
Still, Ardelyx expects the full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million.
The company has development and commercialization agreements with Kyowa Kirin (KYKOF), Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. (KHTRF)
Ardelyx’s Recent Financial Results
The company recently posted its Q2 2024 financial results. The firm reported significant revenue growth, with $73.22 million representing a 228.3% year-over-year increase while beating analysts’ expectations by $18.19 million. R&D expenses and SG&A costs also increased. Yet, the net loss for the quarter of $16.5 million marked a slight improvement over the net loss of $17.1 million during the same period in 2023. GAAP earnings per share (EPS) of -$0.07 outperformed consensus projections of $0.03.
As of the end of the quarter, Ardelyx reported cash, cash equivalents, and short-term investments amounting to $186.0 million.
What Is the Price Target for ARDX Stock?
The stock has been on an upward trajectory, climbing over 336% in the past three years. It trades near the middle of its 52-week price range of $3.16 – $10.13 while showing positive price momentum by trading above its 20-day (6.00) and 50-day (6.09) moving averages. Despite the run-up in price, the stock still appears to trade at a discount to industry peers, with a P/S ratio of 6.8x, well below the Biotechnology industry average of 10.7x.
Analysts following the company have been bullish on ARDX stock. For example, H.C. Wainwright analyst Ed Arce recently raised the price target on the shares from $10 to $11 while maintaining a Buy rating, noting the company’s strong Q2 results.
Ardelyx is rated a Strong Buy based on the recommendations and price targets recently issued by seven analysts. The average price target for ARDX stock is $10.79, representing a potential 75.45% upside from current levels.
Final Analysis on ARDX
Ardelyx (ARDX) offers a compelling story with a robust portfolio of treatments and substantial revenue growth. Furthermore, its potential for continued market expansion marks ARDX as an appealing growth stock for forward-looking investors.
